What to Consider When Choosing a CLL Treatment Path

Published on

Topics include: Treatment

Dr. Jeff Sharman, medical director of hematology research at The US Oncology Network, shares his perspective on the many treatment options now available for patients with CLL and explores how smart combination therapies have revolutionized the way CLL is managed. Dr. Sharman examines the challenges that patient's face when making treatment decisions and discusses factors for patients to consider when choosing a treatment path.

View more programs featuring

Produced in association with

Transcript

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

Andrew Schorr:

And I think that even from the scientific perspective in many cases those answers won't be proven for a number of years.  But in the meantime, we have our clinical hunches and suspicions, and I think it's going to vary depending upon the patient's clinical situation, where they are on their disease, what's approved, what can get insurance authorization, are there specific indications, is it approved only in 17p or all of relapsed CLL, is it frontline—there are too many options to give you a single, pat answer on this. 

But in many cases, what the drug has an FDA-approved label for will be what insurance covers, so that may guide some of the decisions.  But as you can also understand when we meet next year at ASH, those labels will have changed and evolved as new studies become available. 

So your question is have I shot myself in the foot if I get chemotherapy now? I don't think so.  I think that these agents will be approved in the relapsed/refractory setting, and there are so many clinical trial options that primarily focus on patients with relapsed/refractory disease that those will be available to patients who need them down the road. 

Thank you for joining us.  I'm Andrew Schorr.  Remember, knowledge can be the best medicine of all.  

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

Related Programs

The Road from Research to Clinic: Could New CLL Treatments Be Available Soon?

Dr. Jeff Sharman, medical director of hematology research at The US Oncology Network, explores the multitude of new and developing therapies for the treatment of CLL.

Published:

A Chemo-Free Future for Managing CLL?

Dr. Michael Hallek shares news about monoclonal antibody therapies and which patients are benefiting most. He touches on how this may allow doctors to manage CLL without chemotherapy.

Published:

CLL Research: How Far Have We Come? Where Are We Headed?

How far have we come in understanding and treating CLL? Where are we headed? Dr. Michael Keating, a world-renowned expert, explains.

Published:

Advertisement
Join Our Community Register for Events Read Our Latest Blog
Advertisement

Page last updated on March 5, 2014